Series A brings in $6.7mm for Visterra; closes round at $34.2mm
Executive Summary
Three-year-old Visterra Inc. (formerly Parasol Therapeutics; vaccines and diagnostics for infectious diseases) raised $6.7mm in its Series A financing to Flagship Ventures, Lux Capital, and Polaris Venture Partners.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice